Current Research Studies

Cancer – PBTC-042: Phase I Study of CDK 4-6 Inhibitor PD-0332991 In Children With Recurrent, Progressive or Refractory Central Nervous System Tumors

Condition or Therapy:

Central nervous system (CNS) tumors


Cancer and Blood Disorders
Study Number: PBTC-042

What is the goal of this study?

Researchers at Seattle Children's are conducting a phase 1 trial to study the side effects and best dose of an experimental medicine called palbociclib isethionate for treating patients with central nervous system (CNS) tumors that have grown (progressive), come back (recurrent), or have not responded to treatment (refractory)

Who can join the study?

This study might be a good fit for children and young adults who:

  • Are between 4 to 21 years.
  • Have retinoblastoma protein (Rb1) positive recurrent, progressive or refractory CNS tumors

Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for you or your child.

What will happen if my child takes part in this study?

You can read more about this study at

Who can I contact for more information?

To learn more, call 206-987-2106 or send us an email.

Study Location(s):

Seattle Children's Hospital campus

Principal Investigator:

Dr. Sarah Leary